Development of PROSTVAC immunotherapy in prostate cancer.

Abstract

PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

• Authors: Parminder Singh, Sumanta K Pal, Anitha Alex, Neeraj Agarwal
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 15 Pg. 2137-48 ( 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26235179 (Publication Type: Journal Article)

Chemical References

• AR protein, human
• Antibodies, Monoclonal
• Cancer Vaccines
• Ipilimumab
• PROSTVAC
• Receptors, Androgen
• Prostate-Specific Antigen

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Cancer Vaccines (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Genetic Vectors
• Humans
• Immunotherapy
• Ipilimumab
• Male
• Prostate-Specific Antigen (genetics, immunology, therapeutic use)
• Prostatic Neoplasms (immunology, pathology, therapy)
• Receptors, Androgen (genetics)